Avidity Biosciences Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Highlights

SAN DIEGO, Feb. 28, 2023 /PRNewswire/ — Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the fourth quarter and year ended…

Click here to view original post